Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.31 |
| ▸ | USP8 | P40818 | 1/20 | 0.31 |
| ▸ | USP7 | Q93009 | 1/20 | 0.31 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | STAT5B | P51692 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719121 | 0.78 | KMT2A (0.46) | HTTCYP11B1CYP11B2ABL1PIK3CD | |
| SCHEMBL29929823 | 0.78 | EGLN2 (0.42) | CYP11B1CYP11B2ABL1PIK3CDKDM4E | |
| SCHEMBL186339 | 0.78 | EGLN2 (0.42) | CYP11B1CYP11B2ABL1PIK3CDKDM4E | |
| SCHEMBL22865157 | 0.77 | HTT (0.38) | HTTPIK3CDKDM4EALDH1A1POLB | |
| SCHEMBL11031954 | 0.76 | CYP11B1 (0.32) | HTTCYP11B1CYP11B2 | |
| SCHEMBL1976471 | 0.75 | ABL1 (0.35) | CYP11B1CYP11B2ABL1PIK3CDKDM4E | |
| SCHEMBL30834616 | 0.75 | PIK3CD (0.51) | HTTCYP11B1CYP11B2ABL1PIK3CD | |
| SCHEMBL18109302 | 0.75 | PIK3CD (0.51) | HTTCYP11B1CYP11B2ABL1PIK3CD | |
| SCHEMBL10325957 | 0.75 | AGBL2 (0.41) | CYP11B1CYP11B2ABL1PIK3CDKDM4E | |
| SCHEMBL16321670 | 0.75 | ALDH1A1 (0.44) | HTTCYP11B1CYP11B2ABL1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098567-A1 | MACROCYCLIC COMPOUNDS AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12590089-B2 | Processes for preparing toll-like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12565497-B2 | Sulfone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12441754-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2025-10-14 | — | — | US | disclosed |
| EP-4570320-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025087431-A1 | PAN-KRAS INHIBITOR AND USE THEREOF IN MEDICINES | 贝达药业股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-20140113931-A1 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113931-A1 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| WO-2013052394-A1 | 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013052394-A1 | 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-04-11 | — | — | WO | disclosed |
| EP-2408762-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI (FR) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010241-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | US | disclosed |
| WO-2011004132-A1 | NOVEL HSP90-INHIBITING INDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAID DERIVATIVES, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010106290-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | WO | disclosed |
| CN-100494178-C | Preparation method of pyridine formamidine and salt thereof | DONGYANGGUANG PHARMACEUTICAL C (CN) | 2009-06-03 | — | — | CN | disclosed |
| CN-101029023-A | Preparation method of pyridine formamidine and salt thereof | DONGYANGGUANG PHARMACEUTICAL C (CN) | 2007-09-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010241-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | KEAP1 1381/4885HTT 541/4885CYP11B1 345/4885 |
| US-12590089-B2 | Processes for preparing toll-like receptor modulator compounds | TLR8, MYD88, TLR6 | KEAP1 1034/4885HTT 4876/4885CYP11B1 2205/4885 |
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | KEAP1 1756/4885HTT 2970/4885CYP11B1 1405/4885 |
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CCR6 | KEAP1 923/4885HTT 2868/4885CYP11B1 46/4885 |
| US-20140113931-A1 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | SYK, LCK, BTK | KEAP1 2373/4885HTT 3624/4885CYP11B1 4274/4885 |
| US-12441754-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | KEAP1 689/4885HTT 4827/4885CYP11B1 354/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | KEAP1 1980/4885HTT 1624/4885CYP11B1 18/4885 |
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, BCL9, BCL9L | KEAP1 1214/4885HTT 2260/4885CYP11B1 4111/4885 |
| US-12565497-B2 | Sulfone derivatives | CXCR1, CCR1, SULT1E1 | KEAP1 1045/4885HTT 3992/4885CYP11B1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.